Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

CAS No. :	36322-90-4
Formula :	C₁₅H₁₃N₃O₄S
M.W :	331.35
SMILES Code :	O=C(C1=C(O)C2=CC=CC=C2S(N1C)(=O)=O)NC3=NC=CC=C3
Synonyms :	CP-16171; NSC 666076
MDL No. :	MFCD00057317
InChI Key :	QYSPLQLAKJAUJT-UHFFFAOYSA-N
Pubchem ID :	54676228

GHS Pictogram:
Signal Word:	Danger
Hazard Statements:	H301-H373
Precautionary Statements:	P260-P264-P270-P301+P310+P330-P314-P405-P501
Class:	6.1
UN#:	2811
Packing Group:	Ⅲ

Neuro 2A (N-2A) neuroblastoma cells	5 mM	24 hours	To evaluate the protective effects of piroxicam against MPP+ toxicity, results showed piroxicam significantly increased cell viability at 5 mM (from 15±2% to 89±4%)	Neurochem Res. 2009 Feb;34(2):304-10
A-172 cells	3, 14, 30 µM	72 hours	To evaluate the effect of piroxicam on A-172 cells, results showed a protective effect on PBMCs and reduced the fraction of cells in the G2/M phase.	Sci Rep. 2022 Nov 17;12(1):19806
U-87 MG cells	3, 14, 30 µM	72 hours	To evaluate the effect of piroxicam on U-87 MG cells, results showed a protective effect on PBMCs.	Sci Rep. 2022 Nov 17;12(1):19806
Peripheral blood mononuclear cells (PBMCs)	3, 14, 30 µM	72 hours	To evaluate the effect of piroxicam on PBMC proliferation, results showed no adverse effect on proliferation.	Sci Rep. 2022 Nov 17;12(1):19806
Full thickness rat skin	0.5% w/w	8 hours	Assess the permeability of piroxicam through rat skin, with formula F3 showing significantly higher steady-state flux.	Int J Nanomedicine. 2010 Nov 4;5:915-24
Cellulose acetate membrane	0.5% w/w	8 hours	Evaluate the release rate of piroxicam from nanocream, showing that formula F3 released 100% of the drug within 8 hours.	Int J Nanomedicine. 2010 Nov 4;5:915-24

Dogs	Malignant Mesothelioma	Oral	0.3 mg/kg	Daily (dogs) and every other day (cats), for 4 months	To evaluate the efficacy of piroxicam combined with platinum-based chemotherapy for malignant mesothelioma. Results showed that the combination effectively controlled malignant effusion, with one dog remaining in remission after 3 years, while another dog and a cat died due to disease progression after 8 and 6 months, respectively.	J Exp Clin Cancer Res. 2008 May 19;27(1):6
Sprague-Dawley rats	Carrageenan-induced hind paw edema model	Topical application	0.5% w/w	Single dose, lasting 6 hours	Evaluate the anti-inflammatory and analgesic effects of piroxicam nanocream, with formula F3 showing the highest effects.	Int J Nanomedicine. 2010 Nov 4;5:915-24
Male albino mice	Piroxicam-induced liver and kidney injury model	Administered through drinking water	0.8 mg/kg	Daily administration for 6 weeks	To investigate the side effects of piroxicam on liver and kidney functions and evaluate the mitigating effects of selenium-enriched probiotics. Results showed that piroxicam significantly increased levels of urea, creatinine, bilirubin, SGOT, SGPT, and ALP, while selenium-enriched probiotics (especially BSe50/20/1) significantly improved these parameters.	Inflammopharmacology. 2022 Dec;30(6):2097-2106
Charles Foster rats	Middle cerebral artery occlusion (MCAO) model	Intraperitoneal injection	10 mg/kg	Single dose 30 minutes prior to MCAO	To investigate the effects of Piroxicam on 5-hydroxytryptamine (5-HT) levels and its probable GABA agonism following cerebral ischemia. Results showed that Piroxicam pretreatment significantly decreased extracellular 5-HT release in the ischemic cerebral cortex and striatum, suggesting that Piroxicam may reduce 5-HT release through GABA agonism.	Neural Regen Res. 2015 Sep;10(9):1418-20
IL-10-deficient mice	Piroxicam-accelerated colitis model	Standard chow diet	150 mg/kg	10 days	Piroxicam-induced colitis was associated with significant alterations of the intestinal barrier function, including increased permeability, changes in inflammation-related bioactive lipid mediators, and alterations in mucosal CD4+T lymphocyte subsets.	Int J Mol Sci. 2021 Jul 9;22(14):7387
C57/BL6 male mice	MPTP-induced Parkinson's disease model	Intraperitoneal injection	20 mg/kg	3-day pretreatment, continued until the end of the study	To evaluate the protective effects of piroxicam against MPTP-induced SNc dopaminergic neuron degeneration and loss of locomotive function, results showed piroxicam significantly reversed the losses in SNc tyrosine hydroxylase protein expression, SNc DA concentration and associated anomaly in ambulatory locomotor activity	Neurochem Res. 2009 Feb;34(2):304-10
T-cell receptor alpha chain-deficient mice	Model of synchronized colitis	Oral	200 ppm w/w	14 consecutive days	Piroxicam induced a time-prescribed colitis in the proximal colon and cecum of TCR α-deficient mice. Piroxicam administration induced epithelial hyperplasia, goblet cell loss, and leukocyte infiltration with occasional ulceration. Inflammation was multifocal segmental, with areas of tissue damage in between healthy tissue. In addition, variability in the severity of inflammation was observed among replicate animals and treatments, and the administration of dexamethasone only partially ameliorated inflammation in the proximal colon.	Animal Model Exp Med. 2024 Aug;7(4):533-543
Wistar albino male rats	Piroxicam-induced gastric ulcer and hepato-renal toxicity model	Intraperitoneal injection	7 mg/kg	Once daily for 28 days	To investigate the protective effects of CoQ10 against piroxicam-induced oxidative injury and apoptotic pathways. Results showed that piroxicam caused gastric ulceration and hepato-renal damage, which were significantly mitigated by CoQ10.	Biomed Pharmacother. 2020 Oct;130:110627

{[proInfo.proName]}

CAS No.: 36322-90-4

{[proInfo.proName]}

CAS No.: 36322-90-4

Alternative Products

Product Details of Piroxicam

Safety of Piroxicam

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT03038321	Non-Muscle-invasive Bladder Ca... More >>ncer (NMIBC) Bacillus Calmette-Guerin (BCG) Cystitis Intra-vesical Instillation Less <<	Phase 4	Active, not recruiting	December 2019	Egypt ... More >> Urology and Nephrology Center Mansoura, Aldakahlia, Egypt, 35516 Less <<
NCT02457325	Impacted Third Molar Tooth ... More >> Adverse Reaction to Other Local Anesthetics Less <<	Phase 4	Completed	-	-
NCT02160236	Postoperative Pain	Phase 4	Unknown	February 2015	Turkey ... More >> Erciyes Universty Hospital Recruiting Kayseri, Turkey, 38039 Contact: nazife küçük, resident +905072317446 nzfkucuk@hotmail.com Less <<
NCT02191358	-		Completed	-	United States, California ... More >> Dr. Michael Dao Garden Grove, California, United States, 92844 United States, Colorado Kaiser Permanente Colorado Denver, Colorado, United States, 80011 United States, Kentucky Gill Heart Institute Lexington, Kentucky, United States, 40508 United States, Maryland IRC Clinics Towson, Maryland, United States, 21204 United States, Massachusetts Internal Medicine & Cardiology Associates Fall River, Massachusetts, United States, 02720 Prima CARE Fall River, Massachusetts, United States, 02720 United States, Virginia Carilion Clinic Christiansburg, Virginia, United States, 24073 Less <<
NCT00293631	Bunionectomy ... More >>Orthopedic Surgery Less <<	Phase 2	Completed	-	United States, California ... More >> Advanced Clinical Research Institute Anaheim, California, United States, 92801 Less <<
NCT01718756	Closed Non Comminuted Long Bon... More >>e Fractures Less <<	Phase 1 Phase 2	Unknown	February 2016	Egypt ... More >> Anesthesiology Dept., College of Medicine, Mansoura University Recruiting Mansoura, DK, Egypt, 050 Sub-Investigator: Salwa Hawas, MD Principal Investigator: Eiad A Ramzy, MD Sub-Investigator: Douaa G Diab, MD Sub-Investigator: Nahla S El Bahnsawy, MD Sub-Investigator: Hany A Mowafi, MD Sub-Investigator: Talal A Albrahimi, MD Less <<
NCT02025166	Pain	Not Applicable	Unknown	January 2015	Israel ... More >> Rambam Health Care Campus Not yet recruiting Haifa, Israel Contact: Lior Lowenstein, MD, MS 972502061434 l_lior@rambam.health.gov.il Principal Investigator: Susana Mustafa, MD Less <<
NCT01055470	Osteoarthritis of Knee Joint	Not Applicable	Completed	-	India ... More >> Sir Takthasinhji General Hospital Bhavnagar, Gujarat, India, 364001 Less <<
NCT02549118	Analgesia Obs... More >>tetrical Less <<	Phase 2	Unknown	March 2016	-
NCT01069055	Inguinal Hernia ... More >> Postoperative Pain Less <<	Phase 3	Unknown	June 2010	Turkey ... More >> Diskapi Teaching and Research Hospital Not yet recruiting Ankara, Turkey Contact: Alp Alptekin, MD +90 312 5962370 alptekinmd@yahoo.com Contact: Hakan Kulacoglu, MD, FACS hakankulacoglu@hotmail.com Less <<
NCT02750917	Postoperative Pain	Phase 3	Completed	-	-
NCT01564680	Postoperative Pain	Phase 4	Completed	-	Saudi Arabia ... More >> Dammam University, KFHU Al-Khobar, EP, Saudi Arabia, 31952 Less <<
NCT00997750	Acute Coronary Syndrome	Phase 4	Completed	-	Russian Federation ... More >> Central Clinical Hospital of Presidential Department Of Russian Federation Moscow, Russian Federation Less <<
NCT00530387	Dermatitis, Photocontact	Not Applicable	Completed	-	United Kingdom ... More >> Photobiology Unit, Ninewells Hospital, Dundee, Angus, United Kingdom, DD1 9SY Less <<
NCT01480752	Post Operative Endodontic Pain	Phase 2	Completed	-	Iran, Islamic Republic of ... More >> Dental School of Azad University Tehran, Iran, Islamic Republic of, 1946853314 Less <<
NCT01117948	-		Terminated(Lack of Efficacy)	-	-
NCT00293657	Headache (Migraine)	Phase 2	Completed	-	-
NCT03092193	Poor Metabolizer Due to Cytoch... More >>rome P450 CYP2C9 Variant Poor Metabolizer Due to Cytochrome p450 CYP2C19 Variant Less <<	Phase 4	Recruiting	December 2018	Brazil ... More >> Bauru School of Dentistry/USP Recruiting Bauru, São Paulo, Brazil, 17012-901 Contact: Adriana M Calvo, PhD 551432358276 birinjela@yahoo.com.br Less <<
NCT01117948	Alzheimer′s Disease	Phase 2	Terminated(Lack of Efficacy)	-	-
NCT02382653	Neoplasm Metastases	Not Applicable	Completed	-	-
NCT00649415	Dysmenorrhea	Phase 4	Completed	-	Brazil ... More >> Pfizer Investigational Site Salvador, Bahia, Brazil Pfizer Investigational Site Goiania, Goias, Brazil Pfizer Investigational Site Belo Horizonte, Minas Gerais, Brazil, 30130-100 Pfizer Investigational Site Belo Horizonte, Minas Gerais, Brazil, 30130-110 Pfizer Investigational Site Porto Alegre, Rio Grande Do Sul, Brazil, 90610-000 Pfizer Investigational Site Rio De Janeiro, RJ, Brazil, 20551-030 Pfizer Investigational Site Porto Alegre, RS, Brazil Pfizer Investigational Site São Paulo, SP, Brazil Pfizer Investigational Site Sao Paulo, Brazil Pfizer Investigational Site São Paulo, Brazil, 04062-003 Less <<
NCT00631514	Hypertension	Phase 4	Completed	-	Croatia ... More >> Split University School of Medicine. Family Practice Department Split, Croatia, 21000 Less <<
NCT02285972	Injection Pain	Phase 4	Completed	-	Turkey ... More >> Anesthesiology and Reanimation Dept. Ordu University Training and Research Hospital Altınordu, Ordu, Turkey, 52100 Less <<
NCT02304783	Renal Colic	Phase 1 Phase 2	Unknown	March 2018	Tunisia ... More >> Emergency Department of University Hospital of Monastir Recruiting Monastir, Tunisia, 5050 Contact: bzeouich nasri, Resident 52919170 ext 00216 medecinasri@gmail.com Principal Investigator: Nouira Samir, Professor Less <<
NCT00670475	Osteoarthritis of the Knee	Phase 2	Completed	-	Iran, Islamic Republic of ... More >> ArdabiUMS clinic of rheumatology Ardabil, Iran, Islamic Republic of, 56197 Less <<
NCT03745105	Postoperative Pain	Not Applicable	Not yet recruiting	December 1, 2019	-
NCT03626753	Cesarean Section; Complication... More >>s, Wound, Infection (Following Delivery) Postoperative Pain Spinal Anaesthesia During the Puerperium Less <<	Phase 2 Phase 3	Completed	-	Tunisia ... More >> Centre de Maternité de Monastir Monastir, Tunisia, 5000 Less <<
NCT01320709	Contraception, Postcoital	Phase 2	Completed	-	Germany ... More >> Berlin, Germany, 13353 Less <<
NCT03614494	Emergency Contraception	Phase 2 Phase 3	Recruiting	October 30, 2020	Hong Kong ... More >> Queen Mary Hospital Active, not recruiting Hong Kong, Hong Kong The Family Planning Association of Hong Kong Recruiting Hong Kong, Hong Kong Contact: Sue Lo, MD, FRCOG 29197726 stlo@famplan.org.hk Less <<
NCT03006107	Pulpitis - Irreversible	Not Applicable	Unknown	January 2018	-
NCT02450487	Pain\|Other Surgical Procedures... More >>\|Impacted Third Molar Tooth\|Cytochrome P450 CYP2C9 Enzyme Deficiency Less <<	PHASE4	COMPLETED	2025-12-15	-
NCT03612323	Pulpitis - Irreversible	Early Phase 1	Not yet recruiting	August 2019	-
NCT03153657	Tooth Sensitivity ... More >> Toothache Less <<	Phase 3	Completed	-	Brazil ... More >> Hospital Universitário - Universidade Federal de Sergipe Aracaju, Sergipe, Brazil, 490000 Less <<
NCT02253446	Primary Dysmenorrhea	Phase 4	Completed	-	Turkey ... More >> Pamukkale Universty Denizli, Turkey, 20000 Less <<

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	3.02mL 0.60mL 0.30mL	15.09mL 3.02mL 1.51mL	30.18mL 6.04mL 3.02mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed